Will the company take another steep dividend increase? Will the company embark on a more sizeable share buyback program? Will the company make any corporate acquisitions? Pfizer could conceivably do all of the above.
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking "Got It!," you consent to our use of cookies.
Christopher Bell